An experienced investor and entrepreneur in the healthcare field, Brian Frenzel received both bachelor of science and master of business administration degrees from Stanford University. He currently serves as President and CEO Tosk, Inc., a biopharmaceutical discovery and development company. Under Brian Frenzel’s leadership, the company works to improve outcomes for cancer patients by developing new drugs that block the adverse side effects of chemotherapeutic agents, such as cisplatin and carbonation.
Designed to treat and destroy cancer cells in ovarian, bladder, and testicular cancers, among others, cisplatin is an intravenous drug administered under the supervision of an oncologist. Although it is effective in fighting cancer, especially testicular cancer, it can cause a range of side effects, including unusual tiredness and weakness, bleeding and bruising, and hearing loss. Common serious side effects include a loss of balance, joint pain, and swollen or sore legs and feet. Less common serious side effects include convulsions (seizures), loss of reflexes, loss of taste, numbness or tingling in fingers or toes, and trouble in walking. Tosk aims to eliminate most of all of these serious and potentially debilitating side effects.
Brian Frenzel 